<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343117">
  <stage>Registered</stage>
  <submitdate>25/06/2011</submitdate>
  <approvaldate>27/06/2011</approvaldate>
  <actrnumber>ACTRN12611000655943</actrnumber>
  <trial_identification>
    <studytitle>Efficacy of mulberry, red ginseng and banaba in the regulation of blood glucose and insulin responses in type 2 diabetes</studytitle>
    <scientifictitle>A six-month supplementation of mulberry, Korean red ginseng and banaba decreases biomarkers of systemic low grade inflammation in subjects with impaired glucose tolerance and type 2 diabetes</scientifictitle>
    <utrn>U1111-1122-4176</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>type 2 diabetes</healthcondition>
    <healthcondition>Impaired glucose tolerence</healthcondition>
    <conditioncode>
      <conditioncode1>Alternative and complementary medicine</conditioncode1>
      <conditioncode2>Herbal remedies</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>6g/day (2g x 3 times a day) of 1:1:1 mixture of the herbal preparation for 24 weeks. (6g/day of herabl preparation was consisted of 2g/day of Korean red ginseng, 2g/day of Muberry leaf, 2g/day of banaba leaf)


Speficification of herbal preparation:
Korean red ginseng (Panax ginseng C.A. Mayer) powder, mulberry (Morus alba L.) leaf water extract powder, and banaba (Lagerstroemia speciosa L.) leaf water extract powder

The mode of administration: oral capsule</interventions>
    <comparator>Placebo control (corn starch)</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>AUCg (area under the curve of blood glucose) value based on the 75 g oral glucose tolerence test</outcome>
      <timepoint>baseline, 3 months, 6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>AUCi (area under the curve of blood insulin) value</outcome>
      <timepoint>baseline, 3 months, 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>blood inflammation markers:
ICAM, VCAM, ox-LDL, Lp(a), PAI-1, hs-CRP</outcome>
      <timepoint>baseline, 3 months, 6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1) Subjects diagnosed with the impaired glucose tolerence
2) Subjects diagnosed with type 2 diabetes taking one or the combination of following mediations and have not changed the prescription for at least two months.
Mediations: sulfonylurea, biguanide, alpha-gludosidase 
3) Subjects with BMI over 20kg/m2, non-pregnant who has not taken herbs at least for last 3 months</inclusivecriteria>
    <inclusiveminage>35</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>79</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1) Patients taking insulin or medications other than sulfonylurea, biguanide or alpha-glucosidase during last 2 months 
2)Individuals with chronic liver diseases, advanced kidney di se ases, atherosclerosis, myocardial infarction, pulmonary diseases, gastrointestinal diseases, hematological diseases and cancer 
3) Individuals receiving or have received pharmacological doses of steroids and/or participating weight reduction programs</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation involved contacting the holder of the allocation schedule who was at central administration site</concealment>
    <sequence>The randomization was performed using a randomization table generated by using SAS program</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>1/03/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>94</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Korea, Republic Of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Sookmyung Women's University</primarysponsorname>
    <primarysponsoraddress>Department of Food and Nutrition, Sookmyung Women's University, 52 Hyochangwon-gil, Yongsan-gu, Seoul 140-742</primarysponsoraddress>
    <primarysponsorcountry>Korea, Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>The Ministry for Food, Agriculture, Forestry and Fisheries</fundingname>
      <fundingaddress>Gwacheon Government Complex, 88, Gwacheon-si, Gyeonggi-do 427-719</fundingaddress>
      <fundingcountry>Korea, Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Seoul St. Mary's Hospital</sponsorname>
      <sponsoraddress>Department of Endocrinology, The Catholic University of Korea, Seoul St. Mary's Hospital, 505 Banpo-dong, Seocho-gu, Seoul 137-040</sponsoraddress>
      <sponsorcountry>Korea, Republic Of</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To evaluate the long-term efficacy and safety of traditionally used anti-diabetic herbs in controlling blood glucose homeostasis and low grade inflammation, a six month clinical trial was performed with red ginseng roots, mulberry leaf water extract, and banaba leaf water extract in subjects with impaired glucose tolerance or mild cases of T2D.</summary>
    <trialwebsite />
    <publication>N/A</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Institutional Review Board of Seoul St. Mary's Hospital</ethicname>
      <ethicaddress>Seoul St. Mary's Hospital
505 Banpo-dong, Seocho-gu, Seoul 137-040</ethicaddress>
      <ethicapprovaldate>19/04/1997</ethicapprovaldate>
      <hrec>KCMC070T016</hrec>
      <ethicsubmitdate />
      <ethiccountry>Korea, Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mi-Kyung Sung</name>
      <address>52 Hyochangwon-gil, Yongsan-gu, Seoul 140-742</address>
      <phone>+82-2-710-9395</phone>
      <fax>+82-2-710-9453</fax>
      <email>mksung@sm.ac.kr</email>
      <country>Korea, Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sun Choi</name>
      <address>Clinical Research Coordination Center
Seoul St. Mary's Hospital
505 Banpo-dong, Seocho-gu, Seoul 137-040</address>
      <phone>+82-2-590-2679</phone>
      <fax>+82-2-590-2694</fax>
      <email>gomae37@gomae.co.kr</email>
      <country>Korea, Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mi-Kyung Sung</name>
      <address>52 Hyochangwon-gil, Yongsan-gu, Seoul</address>
      <phone>+82-2-710-9395</phone>
      <fax>+82-2-710-9453</fax>
      <email>mksung@sm.ac.kr</email>
      <country>Korea, Republic Of</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>